Asim

Asim, on behalf of Joon Lee from Truist Securities, asked about the primary drivers behind the Firdapse 2026 guidance exceeding historical growth rates, its implications for future growth, and the likelihood of a business development deal in 2026.

Answer

Jeff Del Carmen, EVP and Chief Commercial Officer, attributed Firdapse's strong guidance to the growing pool of identified LEMS patients (over 600), a 21% year-over-year increase in RGCC tests, and enhanced efficiency in patient conversion. Rich Daly, President and CEO, added that the full year impact of dedicated sales forces and pharmacy programs would contribute. Regarding business development, Mr. Daly emphasized a diligent, thoughtful approach focused on differentiated products, partner alignment, and near-term accretive opportunities, without committing to a specific timeline for a deal.

Asim, on behalf of Joon Lee, asked about the key factors driving Firdapse's 2026 growth guidance, which exceeds historical rates, and whether this trajectory is sustainable beyond 2026. He also inquired about the likelihood of Catalyst Pharmaceuticals completing a business development deal in 2026.

Answer

Jeff Del Carmen, EVP and Chief Commercial Officer, highlighted the >600 pool of LEMS patients not yet on treatment and a 21% year-over-year increase in RGCC tests as major confidence drivers. Rich Daly, President and CEO, added that a full year of dedicated sales forces and the pharmacy program (initiated in June 2025) are expected to contribute. For business development, Rich Daly emphasized a diligent, thoughtful approach, prioritizing differentiated products, strategic alignment, near-term accretive opportunities, and assets with peak sales up to $500 million, but did not confirm a deal for 2026.